Skip to content

Greif GEF Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

Constellium logo
ConstelliumCSTM
$28M+86.7%
Sonoco Products logo
Sonoco ProductsSON
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Graco logo
GracoGGG

Other financials

Income statement

See full
Revenue$1.1B-0.5%
Gross profit$247.0M-0.6%
Operating income$35.4M-41.7%
Net income$12.6M-68.4%
EPS (diluted)$1.16-24.6%

Balance sheet

See full
Cash & equivalents$286.1M+42.3%
Total debt$1.2B-60.8%
Total equity$2.9B+44.2%
Total assets$5.6B-15.0%

Cash flow

See full
Operating cash flow$116.6M+479%
CapEx$56.8M+59.1%
Free cash flow$59.8M+190%

Valuation

See full
Market cap$3.92B+19.8%
Enterprise value$4.83B-21.7%
P/E13.1×-3.8×
P/S0.9×+0.1×

Profitability

See full
Gross margin22.4%+1.6pp
Operating margin10.5%+3.4pp
Net margin6.5%+2.3pp
FCF margin5.8%

Returns & leverage

See full
Return on equity12%+2.4pp
Debt / equity0.4×-1.1×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Greif in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Greif’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Greif's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Greif's payments for repurchase of common stock?
Greif (GEF) reported payments for repurchase of common stock of $19.1M in Q1 2026.